Browse the evidence

In healthy lean men, a significant drop in leptin levels during short-term fasting is both necessary and sufficient to trigger physiological adaptations in the hypothalamic-pituitary-gonadal (HPG) and hypothalamic-pituitary-thyroid (HPT) axes, as maintaining leptin levels via replacement-dose recombinant leptin prevents these hormonal changes.

If you are lean and healthy, short-term fasting will cause your sex hormones (testosterone) and thyroid signaling to drop. This is a normal, protective response driven by low leptin levels, not a sign of permanent damage. It is reversible once you resume normal eating.

In healthy lean men, the metabolic and neuroendocrine adaptations of the hypothalamic-pituitary-adrenal (HPA), renin-aldosterone, and growth hormone-IGF-1 axes during short-term fasting are independent of leptin levels.

Fasting affects different hormonal systems differently. While reproductive hormones drop due to low leptin, stress hormones (cortisol) and growth hormone changes happen regardless of leptin levels. Do not assume fixing leptin will fix all hormonal responses to starvation.

Central administration of GLP-1 receptor agonists (specifically liraglutide) stimulates brown adipose tissue (BAT) thermogenesis and white adipose tissue (WAT) browning via a hypothalamic mechanism involving the ventromedial nucleus (VMH) and AMPK dephosphorylation, leading to increased energy expenditure independent of food intake.

GLP-1 agonist medications (like liraglutide or exenatide) do more than just make you feel full; they actively increase your body's energy expenditure by stimulating brown fat activity and 'browning' white fat. This happens through a specific pathway in the brain (hypothalamus). For patients with Type 2 Diabetes, adding these drugs to metformin treatment significantly increases resting energy expenditure compared to metformin alone, contributing to weight loss beyond just eating less.

Chronic hyperglycemia induces mitochondrial ROS production and ER stress, creating a vicious cycle that impairs pancreatic beta-cell function and insulin secretion, leading to Type 2 Diabetes.

To protect your beta-cells, focus on preventing chronic high blood sugar. The paper suggests that keeping glucose levels stable reduces the oxidative stress that damages the cells responsible for making insulin. This means prioritizing a diet that prevents glucose spikes and supports mitochondrial health.

Elevated white blood cell count (WBC), serving as a marker of chronic low-grade inflammation, predicts the development of type 2 diabetes and is associated with a worsening of insulin sensitivity independent of adiposity.

High white blood cell counts are a warning sign for future insulin resistance and type 2 diabetes, even in people who are not yet obese. This suggests that chronic, low-grade inflammation is a key driver of metabolic health. To mitigate this risk, focus on reducing systemic inflammation through anti-inflammatory dietary patterns (rich in omega-3s, fiber, and polyphenols), managing stress, and treating any underlying chronic infections or conditions, rather than focusing solely on weight loss.

Chronic hyperglycemia and subsequent reactive oxygen species (ROS) production cause pancreatic beta-cell dysfunction and insulin resistance in type 2 diabetes by activating the JNK pathway, which suppresses insulin gene transcription and promotes beta-cell apoptosis.

Focus on managing blood glucose levels to reduce the production of reactive oxygen species, which drives beta-cell damage and insulin resistance. While antioxidants are often marketed for health, current evidence suggests they are not sufficient on their own to treat type 2 diabetes; addressing the root cause (hyperglycemia) is essential.

Reactive oxygen species (ROS) derived from NADPH oxidase activation contribute to the progression of atherosclerosis in diabetic patients by promoting endothelial dysfunction, inflammation, and smooth muscle cell proliferation.

Managing diabetes helps reduce the risk of atherosclerosis by lowering ROS production. Genetic factors also play a role in vulnerability, so comprehensive management of blood sugar and blood pressure is important for vascular health.

High-dose aspirin (approx. 7 g/day) improves glucose metabolism in type 2 diabetes by inhibiting the IKKβ serine kinase pathway, thereby reducing hepatic glucose production and enhancing peripheral insulin sensitivity.

This study proves that inhibiting the IKKβ pathway improves insulin sensitivity in type 2 diabetes. However, high-dose aspirin is too toxic for routine use. The practical takeaway is that IKKβ is a valid therapeutic target for developing safer diabetes medications, rather than using aspirin itself.

Administration of recombinant human Fibroblast Growth Factor 19 (FGF19) increases metabolic rate and reverses diet-induced and leptin-deficient diabetes in mice without reducing food intake.

This research identifies FGF19, a hormone, as a potent driver of metabolic rate and glucose control in mice. While not a current human supplement, it suggests that targeting FGF19 pathways could be a viable strategy for treating obesity and type 2 diabetes by increasing energy expenditure rather than restricting food intake.

FGF19 increases metabolic rate and improves glucose homeostasis by increasing fatty acid oxidation and decreasing liver triglycerides, mediated by the suppression of Acetyl CoA Carboxylase 2 (ACC2) and increased leptin receptor expression in the liver.

FGF19 works by telling the liver to burn more fat. It does this by turning off ACC2 (a gatekeeper for fat storage) and turning up leptin receptors (sensitivity to the fat-regulating hormone leptin).

Brown Adipose Tissue (BAT) activation is not essential for FGF19 to increase metabolic rate and reverse obesity/diabetes, as FGF19 remains effective in mice with diminished BAT (UCP-DTA mice).

You don't need 'active' brown fat for FGF19 to help with weight and blood sugar. It works through other pathways, primarily in the liver.

Thiazolidinediones (specifically pioglitazone) improve liver steatosis and inflammation but cause significant weight gain.

Pioglitazone can improve liver inflammation and fat, but it causes significant weight gain. This trade-off makes it less ideal than weight loss alone for many patients. It is a prescription medication, so discuss the risks and benefits with your doctor.

Circulating levels of the ob protein (leptin) and ob mRNA expression in adipose tissue are directly regulated by the state of energy stores, increasing with obesity and decreasing with starvation.

This research confirms that your body produces more of this fat-regulating hormone as you gain weight, not less. This suggests that obesity involves a resistance to this signal rather than a simple deficiency. Therefore, simply taking this hormone as a supplement is unlikely to be effective for weight loss in obese individuals, as the body's response to it is already elevated.

Caloric restriction (CR) extends lifespan and delays age-related diseases in mammals by modulating multiple metabolic pathways, including reduced insulin/IGF-1 signaling, lower thyroid hormone levels, and increased adiponectin, though its translation to human lifespan extension remains unproven.

While rigorous caloric restriction extends lifespan in animals, its effect on human lifespan is unproven. However, moderate caloric restriction combined with exercise can improve healthspan, reduce disease risk, and preserve muscle and bone density in middle-aged adults without the severe side effects of extreme dieting.

Attenuated Insulin/IGF-1 Signaling (IIS) extends lifespan in model organisms, but in humans, low IGF-1 is associated with increased risk of cardiovascular disease, diabetes, and osteoporosis, creating a paradox where the mechanism that extends lifespan in animals may be detrimental in humans.

While reducing IIS extends lifespan in animals, humans with naturally low IGF-1 face higher risks of heart disease, diabetes, and bone loss. Therefore, simply trying to lower insulin/IGF-1 or boost it via GH therapy without medical supervision is not a straightforward longevity strategy for humans.

Obesity-associated insulin resistance is driven by the failure of adipose tissue expandability, which causes nutrient leakage and lipotoxicity in non-adipose organs, rather than by adipose mass alone.

Focus on improving adipose tissue health and capacity rather than just reducing total fat mass. Strategies that support safe lipid storage (e.g., through specific dietary patterns or medications that enhance adipose expandability) may be more effective for metabolic health than weight loss alone, which can sometimes exacerbate lipotoxicity if not managed correctly.

Adipose tissue plasticity and the production of specific adipokines (e.g., TNF-alpha, resistin) contribute to insulin resistance by impairing adipose tissue function and limiting further expansion.

Managing obesity may require addressing the hormonal signals from fat tissue, not just the fat itself. Some medications aim to improve adipose tissue function and reduce harmful adipokine production.

Twelve weeks of combined endurance and strength training in humans does not increase circulating irisin levels and may actually reduce them, despite increasing muscle FNDC5 mRNA expression.

If you are training to boost irisin for fat loss, this 12-week study suggests it won't work as expected; irisin levels actually decreased. However, your muscle genes (PGC1A and FNDC5) did upregulate. Focus on the direct metabolic benefits of exercise rather than expecting a specific hormonal spike in irisin.

Acute exercise (45 min at 70% VO2max) causes a transient ~1.2-fold increase in plasma irisin immediately post-exercise, which returns to baseline within 2 hours.

If you measure irisin right after a hard workout, it will be slightly higher. However, this spike is short-lived and does not persist, suggesting it is not a primary driver of long-term metabolic adaptation via this specific hormone.

Chronic exercise training increases muscle PGC1A and FNDC5 mRNA expression in humans, but this transcriptional increase does not correlate with plasma irisin levels or subcutaneous fat browning (UCP1).

Your muscles do adapt to exercise by increasing the machinery (PGC1A/FNDC5 mRNA) to potentially produce irisin. However, this does not mean more irisin enters your blood or that your fat turns brown. The local muscle changes are real, but the systemic hormonal effect is not.

A simple index derived from the first 30 minutes of an Oral Glucose Tolerance Test (OGTT), calculated as the product of the area under the curve (AUC) for glucose and insulin, accurately quantifies hepatic (liver) insulin resistance.

If you are at risk for diabetes or metabolic syndrome, a standard Oral Glucose Tolerance Test (OGTT) can reveal liver-specific insulin resistance. By analyzing the first 30 minutes of your blood sugar and insulin response, doctors can identify liver dysfunction earlier and more accurately than with fasting tests alone, allowing for targeted lifestyle or medical interventions to prevent type 2 diabetes.

A specific index derived from the decline phase of an Oral Glucose Tolerance Test (OGTT), calculated as the rate of glucose decline divided by mean insulin concentration, accurately quantifies skeletal muscle insulin sensitivity.

If you are at risk for diabetes or metabolic syndrome, a standard Oral Glucose Tolerance Test (OGTT) can reveal muscle-specific insulin resistance. By analyzing how quickly your blood sugar drops after the peak and dividing that by your insulin levels, doctors can identify muscle dysfunction earlier and more accurately than with fasting tests alone, allowing for targeted lifestyle or medical interventions to prevent type 2 diabetes.

Transdermal estrogen does not significantly increase the risk of venous thromboembolism in postmenopausal women, unlike oral estrogen.

If you are using transdermal estrogen (patches or gels), your risk of blood clots is not significantly increased compared to women not using hormones. This makes transdermal estrogen a safer choice than oral estrogen for postmenopausal women concerned about thromboembolism, especially those with other risk factors like obesity or genetic mutations.

Leptin resistance in obesity is mechanistically linked to the overexpression of negative regulators of leptin signaling, specifically SOCS-3 and PTP1B, in the hypothalamus.

Leptin resistance isn't just about 'willpower'; it involves specific proteins (SOCS-3, PTP1B) that block the signal in your brain. Research is targeting these specific proteins to develop drugs that could restore sensitivity.